AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...

AbbVie is transitioning immunology sales to new and more effective treatments, ... (up 24%) continues to benefit from label expansion into major depression.

The company expects its newer immunology duo of Rinvoq and Skyrizi to pull down $27 billion by 2027, far eclipsing Humira's 2022 peak of $21 billion. Last year, the duo generated nearly $12 billion.

On July 25, AbbVie released its Q2 2024 financial results, which surprised me with surging sales of its immunology and neuroscience franchises. So, Rinvoq's sales amounted to $1.43 billion for the ...

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion.

Wells Fargo analyst Mohit Bansal has maintained their bullish stance on ABBV stock, giving a Buy rating today. Mohit Bansal has given his Buy rating due to a combination of factors that enhance ...